Evidence map›Paper›PMID 30734201›Full record

ArticleInvestigational new drugs2019

Delineation of proapoptotic signaling of anthracene-shelled M

Rositsa Mihaylova, Anife Ahmedova, Denitsa Momekova, Georgi Momekov, Nikolay Danchev

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rositsa MihaylovaDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Street, 1000, Sofia, Bulgaria.
Anife AhmedovaLaboratory of Biocoordination and Bioanalytical Chemistry, Faculty of Chemistry and Pharmacy, "St. Kliment Ohridski" Sofia University, 1, J. Bourchier Blvd., 1164, Sofia, Bulgaria.
Denitsa MomekovaDepartment of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Street, 1000, Sofia, Bulgaria.
Georgi MomekovDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Street, 1000, Sofia, Bulgaria. gmomekov@gmail.com.
Nikolay DanchevDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Street, 1000, Sofia, Bulgaria.
Medical University of Sofia · BGSofia University "St. Kliment Ohridski" · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the introduction of cisplatin into clinical practice a few decades ago, the topic of metal-based drugs has expanded significantly. Recent examples emphasize on metallosupramolecules as an emerging class of compounds with diverse properties. They can trigger unique cellular events in malignant cells or serve as molecular hosts for various biologically active compounds, including anticancer agents. The anthracene-shelled M

Indexed as

AnthracenesAntineoplastic AgentsApoptosisCapsulesCisplatinCurcuminDrug Resistance, NeoplasmDrug SynergismHL-60 CellsHT29 CellsHumansSignal TransductionanthraceneAnthracenesAntineoplastic AgentsCapsulesCisplatinCurcuminApoptosisCisplatin resistanceCollateral sensitivityCurcuminMetallosupramoleculesSynergism

Identifiers

PMID30734201
OpenAlexW2914721149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.